Having trouble accessing articles? Reset your cache.

Herceptin trastuzumab regulatory update

The U.K's NICE issued a final appraisal determination (FAD) recommending Herceptin trastuzumab in a more limited population than its approved indication, for which NICE rebuffed

Read the full 253 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE